February 10, 2021
Chugai Pharmaceutical on February 9 released the results from a Japan PIII study of its humanized anti-human IL-6 receptor monoclonal antibody Actemra (tocilizumab) in patients with COVID-19 associated pneumonia. The company is planning for the Japanese regulatory submission of this...read more